On 2017 Jan 31, Stuart RAY commented:

This is a very interesting and well-done study of a model system. That said, the unqualified use of the terms "antiviral effects of IFN-lambda" and "norovirus" in the title of this article might be misleading without context. Readers should be alert: (a) the noroviruses are very diverse biologically and phylogenetically; (b) murine norovirus is distinct from human noroviruses in apparent tropism, binding (sialic vs blood group antigens), pH dependence of viral entry (Kim Y. Green, Fields Virology 2013, chapter 20); (c) there are significant biological differences between human and mouse responses to lambda interferon (Hermant P, 2014); and B6 mice lack functional MX1 (Pillai PS, 2016, Moritoh K, 2009). Given differences in virus and host, whether the findings presented by Baldridge et al. can be extrapolated to other systems (e.g. natural human norovirus infection) is highly uncertain; therefore, I suggest that the title should end with "in mice".

On 2017 Jan 31, Stuart RAY commented:

This is a very interesting and well-done study of a model system. That said, the unqualified use of the terms "antiviral effects of IFN-lambda" and "norovirus" in the title of this article might be misleading without context. Readers should be alert: (a) the noroviruses are very diverse biologically and phylogenetically; (b) murine norovirus is distinct from human noroviruses in apparent tropism, binding (sialic vs blood group antigens), pH dependence of viral entry (Kim Y. Green, Fields Virology 2013, chapter 20); (c) there are significant biological differences between human and mouse responses to lambda interferon (Hermant P, 2014); and B6 mice lack functional MX1 (Pillai PS, 2016, Moritoh K, 2009). Given differences in virus and host, whether the findings presented by Baldridge et al. can be extrapolated to other systems (e.g. natural human norovirus infection) is highly uncertain; therefore, I suggest that the title should end with "in mice".